How many drugs treat Urticaria?

Drug Landscape tracks 10 marketed treatments for Urticaria (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/urticaria.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Urticaria — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urticaria (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Urticaria, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Rupax	RUPATADINE	Teikoku Seiyaku	rupatadine	Histamine H1 receptor	2001-01-01
Emadine	EMEDASTINE	Novartis	Histamine-1 Receptor Inhibitor	Histamine H1 receptor	1997-01-01
Phenazoline	ANTAZOLINE	Novartis	antazoline	Histamine H1 receptor	1990-01-01
Actidil	TRIPROLIDINE	Novartis	triprolidine	Histamine H1 receptor	1983-01-01
Hispril	DIPHENYLPYRALINE	GSK	diphenylpyraline	Histamine H1 receptor	1982-01-01
Karbinal Er	CARBINOXAMINE	Mcneil	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1974-01-01
Pyrilamine	mepyramine	Impax Labs	Central Nervous System Stimulant [EPC]	Histamine H1 receptor	1973-01-01
Drixoral	DEXBROMPHENIRAMINE	Merck & Co.	dexbrompheniramine	Histamine H1 receptor	1963-01-01
Hydroxyzine Hydrochloride	HYDROXYZINE	Pfizer	Antihistamine	Histamine H1 receptor	1956-01-01
Phenergan	promethazine	Generic (originally Wyeth/Pfizer)	Phenothiazine antihistamine/antiemetic	Aldehyde oxidase, 5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR	1951-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 10 drugs in Urticaria
Novartis · 4 drugs in Urticaria
Bayer · 2 drugs in Urticaria
GSK · 1 drug in Urticaria
Generic (originally Wyeth/Pfizer) · 1 drug in Urticaria
Impax Labs · 1 drug in Urticaria
King Faisal Specialist Hospital & Research Center · 1 drug in Urticaria
Marcus Maurer · 1 drug in Urticaria
Mcneil · 1 drug in Urticaria
Merck & Co. · 1 drug in Urticaria
Pfizer · 1 drug in Urticaria
St. Petersburg Bekhterev Research Psychoneurological Institute · 1 drug in Urticaria

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Urticaria:

Cite this brief

Drug Landscape (2026). Urticaria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/urticaria. Accessed 2026-06-10.

Urticaria full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing